This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

The chemotherapy agents 5-fluorouracil, gemcitabine, capecitabine and paclitaxel have all proven to be efficacious when combined with radiation. Gemcitabine is a pyrimidine analog that was ...

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

Perioperative durvalumab improved upon neoadjuvant chemotherapy in patients with cisplatin-eligible MIBC in the NIAGARA trial.

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

1月28日，ImmunoMet Therapeutics公布其在研小分子Lixumistat联合吉西他滨（Gemcitabine）和白蛋白结合型紫杉醇（Nab-paclitaxel），作为一线疗法治疗晚期胰腺癌患者的结果。 胰腺癌因发病隐匿，恶性程度极高，预后效果极差，被称为“癌症之王”。近年来，针对胰腺癌的创新疗法不断增多，为胰腺癌治疗提供了新的选择。 近期，在研小分子Lixumistat联合吉 ...

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...

The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...